# MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer

> **NCT03767335** · PHASE1 · COMPLETED · sponsor: **Menarini Group** · enrollment: 62 (actual)

## Conditions studied

- Advanced or Metastatic Breast Cancer

## Interventions

- **DRUG:** MEN1611
- **DRUG:** Trastuzumab
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT03767335
- **Lead sponsor:** Menarini Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-13
- **Primary completion:** 2024-02-23
- **Final completion:** 2024-02-23
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2025-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03767335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03767335, "MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03767335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*